France Secures Continued Wegovy Access Pending Price Negotiation
Novo Nordisk will continue providing free Wegovy to 3,000 French patients until at least December 2025 while negotiating a price for national reimbursement, following a positive review by the Haute Autorité de santé (HAS) in December 2024 and initial access for nearly 10,000 patients through an earl...
France Secures Continued Wegovy Access Pending Price Negotiation
Novo Nordisk will continue providing free Wegovy to 3,000 French patients until at least December 2025 while negotiating a price for national reimbursement, following a positive review by the Haute Autorité de santé (HAS) in December 2024 and initial access for nearly 10,000 patients through an earl...
Progress
32% Bias Score
CMS Drug Price Controls Under IRA Threaten Pharmaceutical Innovation
CMS announced price negotiations for 15 drugs under the IRA, imposing penalties up to 95% of U.S. sales for non-compliance; this discourages R&D, potentially resulting in fewer new drugs and harming patients, with studies projecting a loss of 135 new drugs and $663 billion in R&D spending by 2039.
CMS Drug Price Controls Under IRA Threaten Pharmaceutical Innovation
CMS announced price negotiations for 15 drugs under the IRA, imposing penalties up to 95% of U.S. sales for non-compliance; this discourages R&D, potentially resulting in fewer new drugs and harming patients, with studies projecting a loss of 135 new drugs and $663 billion in R&D spending by 2039.
Progress
60% Bias Score
Medicare Price Negotiations Expand to 15 Drugs, Including Ozempic and Wegovy
The Biden administration announced 15 drugs, including Ozempic and Wegovy, for Medicare price negotiations under the Inflation Reduction Act, aiming to lower drug costs for 50 million beneficiaries; the new prices are expected to take effect in January 2027, although the incoming Trump administratio...
Medicare Price Negotiations Expand to 15 Drugs, Including Ozempic and Wegovy
The Biden administration announced 15 drugs, including Ozempic and Wegovy, for Medicare price negotiations under the Inflation Reduction Act, aiming to lower drug costs for 50 million beneficiaries; the new prices are expected to take effect in January 2027, although the incoming Trump administratio...
Progress
36% Bias Score
Medicare to Negotiate Prices for Ozempic, Wegovy, and 13 Other Drugs
Medicare will negotiate prices for Ozempic, Wegovy, and 13 other drugs, impacting 5.3 million Part D users and $41 billion in drug costs, with negotiated prices effective in 2027.
Medicare to Negotiate Prices for Ozempic, Wegovy, and 13 Other Drugs
Medicare will negotiate prices for Ozempic, Wegovy, and 13 other drugs, impacting 5.3 million Part D users and $41 billion in drug costs, with negotiated prices effective in 2027.
Progress
32% Bias Score
Future of Medicare Drug Price Negotiations Uncertain Under Trump
Medicare's new drug price negotiation program, enacted under the Inflation Reduction Act, faces an uncertain future under the incoming Trump administration; while it lowered prices on 10 drugs in 2023, and aims to lower prices on 15 more in 2027, Republican efforts to repeal it are underway.
Future of Medicare Drug Price Negotiations Uncertain Under Trump
Medicare's new drug price negotiation program, enacted under the Inflation Reduction Act, faces an uncertain future under the incoming Trump administration; while it lowered prices on 10 drugs in 2023, and aims to lower prices on 15 more in 2027, Republican efforts to repeal it are underway.
Progress
52% Bias Score
Medicare Part D Drug Cost Cap Set at $2,000 Annually Starting in 2025
The Inflation Reduction Act institutes a $2,000 annual out-of-pocket cap on Medicare Part D prescription drug costs starting in 2025, benefiting over 3 million enrollees without low-income subsidies, with this number projected to reach over 4 million by 2029; insurers will cover 60% of costs in the ...
Medicare Part D Drug Cost Cap Set at $2,000 Annually Starting in 2025
The Inflation Reduction Act institutes a $2,000 annual out-of-pocket cap on Medicare Part D prescription drug costs starting in 2025, benefiting over 3 million enrollees without low-income subsidies, with this number projected to reach over 4 million by 2029; insurers will cover 60% of costs in the ...
Progress
48% Bias Score
£60,000 Alzheimer's Drug Faces Criticism Over Limited Benefits and High Risks
A new £60,000-a-year Alzheimer's drug, Donanemab, offered privately in London, is criticized for minimal benefits and risks like brain swelling and bleeding, despite UK regulator approval; NHS rejected it due to cost-ineffectiveness.
£60,000 Alzheimer's Drug Faces Criticism Over Limited Benefits and High Risks
A new £60,000-a-year Alzheimer's drug, Donanemab, offered privately in London, is criticized for minimal benefits and risks like brain swelling and bleeding, despite UK regulator approval; NHS rejected it due to cost-ineffectiveness.
Progress
60% Bias Score
FTC Accuses PBMs of \$8.7 Billion in Price Gouging
The FTC released a report accusing the three largest Pharmacy Benefit Managers (PBMs)—OptumRx, Express Scripts, and CVS Caremark—of marking up specialty generic drug prices by over \$7.3 billion from 2017-2022, and an additional \$1.4 billion through spread pricing, ultimately increasing patient cos...
FTC Accuses PBMs of \$8.7 Billion in Price Gouging
The FTC released a report accusing the three largest Pharmacy Benefit Managers (PBMs)—OptumRx, Express Scripts, and CVS Caremark—of marking up specialty generic drug prices by over \$7.3 billion from 2017-2022, and an additional \$1.4 billion through spread pricing, ultimately increasing patient cos...
Progress
24% Bias Score
Medicare Selects 15 More Drugs for Price Negotiation
Medicare selected 15 more top-selling prescription drugs for price negotiations under the Inflation Reduction Act, impacting 5.3 million beneficiaries and $41 billion in spending, with expected savings of $1.5 billion in 2027, but the incoming Trump administration may alter the program.
Medicare Selects 15 More Drugs for Price Negotiation
Medicare selected 15 more top-selling prescription drugs for price negotiations under the Inflation Reduction Act, impacting 5.3 million beneficiaries and $41 billion in spending, with expected savings of $1.5 billion in 2027, but the incoming Trump administration may alter the program.
Progress
48% Bias Score
California's Affordable Insulin Plan Faces Delays
California's plan to produce cheap insulin by 2024 is delayed due to the time needed for clinical trials and FDA approval, impacting 3.2 million diabetics and exceeding the projected timeline by at least one year.
California's Affordable Insulin Plan Faces Delays
California's plan to produce cheap insulin by 2024 is delayed due to the time needed for clinical trials and FDA approval, impacting 3.2 million diabetics and exceeding the projected timeline by at least one year.
Progress
44% Bias Score
Defeated PBM Reform Bill Fails to Address Core Issues
The FTC's July 2024 report criticized PBM practices, leading to a lawsuit; a defeated bill (HR II Section 227) attempted reform but failed to address core issues like rebates and transparency, potentially increasing costs and administrative burden.
Defeated PBM Reform Bill Fails to Address Core Issues
The FTC's July 2024 report criticized PBM practices, leading to a lawsuit; a defeated bill (HR II Section 227) attempted reform but failed to address core issues like rebates and transparency, potentially increasing costs and administrative burden.
Progress
56% Bias Score
Pharmaceutical Industry Faces 2025 Inflection Point Amidst Global Cost Pressures
Global pharmaceutical manufacturers face increasing pressure to lower drug prices in 2025 due to government regulations (e.g., the Inflation Reduction Act), payer consolidation, and consumer cost concerns; requiring manufacturers to prioritize long-term value, evidence-based decision-making, and str...
Pharmaceutical Industry Faces 2025 Inflection Point Amidst Global Cost Pressures
Global pharmaceutical manufacturers face increasing pressure to lower drug prices in 2025 due to government regulations (e.g., the Inflation Reduction Act), payer consolidation, and consumer cost concerns; requiring manufacturers to prioritize long-term value, evidence-based decision-making, and str...
Progress
44% Bias Score